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Abstract
Background: Apical membrane antigen 1 (AMA-1) and merozoite surface protein 1 (MSP1) of Plasmodium falciparum 
are two leading blood-stage malaria vaccine candidates. A P. falciparum chimeric protein 2.9 (PfCP-2.9) has been 
constructed as a vaccine candidate, by fusing AMA-1 domain III (AMA-1 (III)) with a C-terminal 19 kDa fragment of MSP1 
(MSP1-19) via a 28-mer peptide hinge. PfCP-2.9 was highly immunogenic in animal studies, and antibodies elicited by 
the PfCP-2.9 highly inhibited parasite growth in vitro. This study focused on locating the distribution of epitopes on 
PfCP-2.9.
Methods: A panel of anti-PfCP-2.9 monoclonal antibodies (mAbs) were produced and their properties were examined 
by Western blot as well as in vitro growth inhibition assay (GIA). In addition, a series of PfCP-2.9 mutants containing 
single amino acid substitution were produced in Pichia pastoris. Interaction of the mAbs with the PfCP-2.9 mutants was 
measured by both Western blot and enzyme-linked immunosorbent assay (ELISA).
Results: Twelve mAbs recognizing PfCP-2.9 chimeric protein were produced. Of them, eight mAbs recognized 
conformational epitopes and six mAbs showed various levels of inhibitory activities on parasite growth in vitro. In 
addition, seventeen PfCP-2.9 mutants with single amino acid substitution were produced in Pichia pastoris for 
interaction with mAbs. Reduced binding of an inhibitory mAb (mAb7G), was observed in three mutants including M62 
(Phe491TAla), M82 (Glu511TGln) and M84 (Arg513TLys), suggesting that these amino acid substitutions are critical to 
the epitope corresponding to mAb7G. The binding of two non-inhibitory mAbs (mAbG11.12 and mAbW9.10) was also 
reduced in the mutants of either M62 or M82. The substitution of Leu31 to Arg resulted in completely abolishing the 
binding of mAb1E1 (a blocking antibody) to M176 mutant, suggesting that the Leu residue at this position plays a 
crucial role in the formation of the epitope. In addition, the Asn15 residue may also play an important role in the global 
folding of PfCP-2.9, as its substitution by Arg lead to reduced binding of most mAbs and abolishing the binding of 
mAb6G and mAbP5-W12.
Conclusions: This study provided valuable information on epitopes of PfCP-2.9 vaccine candidate through generation 
of a panel of mAbs and a series of PfCP-2.9 mutants. The information may prove to be useful for designing more 
effective malaria vaccines against blood-stage parasites.
Background
Malaria remains a severe tropical disease. It causes about 
247 million cases in the world and nearly a million deaths 
in 2006, most of which were in children under five years 
of age in sub-Saharan Africa [1]. The Plasmodium para-
site of malaria has a complex life cycle, and the blood 
stage is believed to be responsible for the disease and 
directly associated with clinical manifestations and there-
fore considered as a primary target for developing 
malaria vaccines.
Apical membrane antigen 1 (AMA-1) and merozoite sur-
face protein 1 (MSP1) of Plasmodium falciparum play 
essential roles in the blood stage of malarial life cycle and 
are two promising vaccine candidates [2,3]. After a simi-
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lar proteolytic processing step by P. falciparum subtilisin-
like protease 2 (PfSUB2) [4,5], their C-terminal regions 
remain anchored within the parasite membrane, and then 
are carried into the newly invaded red blood cells [6,7]. 
Plasmodium falciparum chimeric protein 2.9 (PfCP-2.9) 
constructed by fusing PfAMA-1 (III) with PfMSP1-19 in 
previous studies [8,9], was shown to enhance the product 
yield, immunogenicity, and antibody-mediated in vitro 
growth inhibition assays (GIA). When formulated with 
Montanide ISA720, the vaccine was also confirmed to be 
safe, tolerable and immunogenic in two Phase I clinical 
trials [10,11]. Although higher levels of antibody titers are 
usually associated with better protection, some research-
ers argued that fine specificity of antibodies was closely 
associated with biological functions [12-14]. As described 
by Uthaipibull et al [13], antibodies to PfMSP1-19 could 
be classified as inhibitory (inhibiting secondary process-
ing and/or erythrocyte invasion), blocking (blocking the 
function of inhibitory antibodies) and neutral (neither 
inhibitory nor blocking). It was proposed that there may 
also exist malaria specific non-AMA-1 blocking antibod-
ies, because it was found that a fraction of malaria spe-
cific immunoglobulins (IgGs) from Malians that did not 
bind to AMA-1 substantially reduced the growth-inhibi-
tory activity of both total IgGs and anti-AMA-1 antibod-
ies from the sera of U.S. vaccinees [15]. Therefore, fine 
epitope mapping of the PfCP-2.9 protein is needed for 
further development of the vaccine candidate.
Some epitopes of PfMSP1-19 have been described previ-
ously, especially since the discovery of the three-dimen-
sional structure of the molecule [16-19]. PfMSP1-19 
consists of two epidermal-growth-factor (EGF)-like 
domains, forming a disc-like shaped molecule. Inhibitory 
monoclonal antibodies (mAbs), including 12.8 and 12.10, 
recognize conformational epitopes on one side of the 
molecule, while blocking or neutral mAbs seem to recog-
nize epitopes localized on the other side. The difference 
in distribution of the inhibitory and neutral epitopes is 
consistent with the formation of a ring structure between 
PfMSP1-19 and both 2F10 (neutral) and 12.10 (inhibi-
tory) antibodies [12]. The structure of PfAMA-1 (III) has 
also been resolved, although its functional epitopes 
remain unknown [20].
It was found in a previous study [9] that PfCP-2.9 main-
tained the important conformational epitopes on 
PfMSP1-19 through interaction with a panel of confor-
mational mAbs and displayed elevated biological activity 
compared with the two components. However, functional 
epitopes on PfCP-2.9 remain unclear. In this study, a 
panel of anti-PfCP-2.9 mAbs and a series of mutated pro-
teins with single amino acid substitution on PfCP-2.9 
were prepared to clarify the distribution of epitopes on 
PfCP-2.9.
Methods
Generation of hybridomas and production of mAbs to 
PfCP-2.9
A panel of mAbs to the PfCP-2.9 were produced in this 
study by the hybridoma technology as previously 
described [21]. Briefly, BALB/c mice were immunized by 
administration of 50 μg PfCP-2.9 in the presence of FCA 
(Freund's complete adjuvant)/FIA (Freund's incomplete 
adjuvant), followed by three booster injections of the 
same dose at 15-day intervals. Spleen cells were separated 
from mice 3 days after the last immunization and fused 
with SP2/0 mouse myeloma cells. The hybrids were then 
selected in hypoxanthine-aminopterin-thymidine (HAT) 
medium and cloned by limiting dilution. For large-scale 
production, hybridoma cell lines were abdominally 
injected into mice to generate mAbs in ascites. The mAbs 
were further purified by protein G affinity chromatogra-
phy, dialyzed against RPMI 1640 media, aliquoted and 
stored at -80°C.
Parasite cultures and GIA
Plasmodium falciparum FCC1/HN strain was main-
tained and used for the assay [9]. Synchronized parasites 
were cultured until the mature trophozoite stage of devel-
opment. 100 μl culture containing 2% RBC with a 0.5% ± 
0.1% initial parasitemia and 25 μl of test mAbs was added 
to 96-well flat-bottomed plates (Greiner Bio-one, Ger-
many). The initial concentrations of the test mAbs were 
adjusted to 2 mg/ml before the assay. IgG of rabbit anti-
AMA1-C1 (2 mg/ml) was used as an inhibitory control 
(gift of NIH) and mAb5.2 was used as a non-inhibitory 
control. All the mAbs were sterilized by filtration through 
a 0.22 μm Millex-GV filter (Millipore, USA). After 42-h 
incubation with the purified antibody, 50 μl well-mixed 
parasites from each assay well were dispensed into 0.25 
ml cold phosphate buffered saline (PBS, pH 7.4) in a fresh 
96-well U-bottomed ELISA microplate (Greiner Bio-one, 
Germany). The plates were loaded into a Centrifuge 
5810R (Eppendorf, Germany) and centrifuged at 1,300 × g 
for 10 min at 4°C. A portion (0.24 ml) of the supernatant 
was removed from each well, and the plate was frozen at -
80°C for 30 min to lyse the pelleted cells. After the plate 
was brought back to room temperature (RT), 0.1 ml com-
plete pLDH substrate (100 mM Tris-HCl pH 7.5, 50 mM 
sodium L-lactate, and 0.25% Triton X-100 containing 0.2 
mg nitroblue tetrazolium ml-1, 0.05 mg 3-acetylpyridine 
adenine dinucleotide ml-1, and 1 U Diaphorase ml-1) was 
added to each well. The plate was kept in the dark and 
read at 15 and 30 min. The absorbance of wells in each 
plate was measured at 650 nm on a Microplate reader 
(ELx800 ELISA reader; Bio-Tek Instruments, Winooski, 
VT), and the percentage of inhibition was calculated as 
100 - (A650 of the test sample - A650 of the RBC only)/(A650 
of mAb5.2 - A650 of RBC only) ×100.Li et al. Malaria Journal 2010, 9:94
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Mutagenesis
The pfcp-2.9 gene [9] was mutated by site-directed muta-
genesis using Pichia optimized codons by overlap exten-
sion polymerase chain reaction (PCR) [22], based on the 
rule of "safe substitution" [23], which would minimally 
affect the global folding of the target protein. The con-
structed plasmid vector of pfcp-2.9/pBluescriptKS was 
amplified by KOD-plus DNA polymerase (Toyobo, 
Osaka, Japan) with the mutant primers listed in Table 1. 
Then the mutated genes were transformed into compe-
tent Escherichia coli DH5α cells (Life technologies). After 
screening by analysis of restriction enzyme digests, the 
sequence of selected mutant clones was confirmed using 
an Applied Biosystems ABI 377 DNA sequencer accord-
ing to the manufacturer's instructions.
Protein expression and purification
Each mutated 6×His tagged gene was cloned into the 
expression vector of pPIC9K and linearized via SacI 
digestion. After transformation into Pichia pastoris by 
electroporation, selection of His+ transformants and 
G418-resistant clones was performed according to the 
manufacturer's instructions (Invitrogen, San Diego, CA). 
The selected clone was grown in minimal glycerol 
medium at 30°C overnight and then resuspended in buff-
ered methanol-complex medium containing 0.5% metha-
nol to induce expression of the target gene. After 72-h 
induction, the supernatant was collected by centrifuga-
tion at 10,000 × g for 10 min, and then dialyzed against 
lysis buffer (50 mM NaH2PO4, 300 mM NaCl, pH 8.0) at 
4°C overnight. Filtration was performed with a micropo-
rous membrane (0.22 μm in diameter) before the protein 
was purified by Ni-NTA affinity chromotography. Elution 
was performed with elution buffer (lysis buffer containing 
50~250 mM imidazole, pH 8.0) after the column was 
equilibrated by lysis buffer and washed extensively with 
wash buffer (lysis buffer containing 10 mM imidazole, pH 
8.0).
Analysis of antibody binding to PfCP-2.9 and mutated 
proteins by Western blot and ELISA
Purified protein samples were subjected to sodium dode-
cyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE) after boiling in the sample buffer without a reduc-
ing agent. The protein bands were electrophoretically 
transferred to the nitrocellulose membrane (Huashun, 
China) by the Trans-blot SD semi-dry transfer cell (Bio-
rad, USA). Blots were blocked with Tris-buffered saline 
(TBS, pH 7.4) containing 3% skim milk (TBS-M) at RT 
for 1 h; washed with TBS containing 0.05% Tween 20 
(TBS-T) for three times and then probed by the primary 
antibody in TBS-M at RT for 2 h. The blots were washed 
and incubated with alkaline phosphatase (AP)-conju-
gated goat anti-mouse IgG (H+L) (Jackson ImmunoRe-
search, USA) at a 1:1000 dilution for 1 h, followed by 
three washes in TBS-T and in AP buffer (100 mM NaCl, 5 
mM MgCl26H2O, 100 mM TrisCl, pH 9.5) for 10 min. 
Finally, antibody binding was detected by nitrotetrazo-
lium blue chloride (NBT)/5-bromo-4-chloro-3-indo-
lylphosphate (BCIP) (Genview, USA) substrate in AP 
buffer (66 μl NBT/33 μl BCIP/10 ml AP buffer) and ter-
minated by washing with double distilled water. For qual-
itative comparison, proteins were analyzed on a SDS-
PAGE gel to obtain an equal amount. Antibody binding to 
PfCP-2.9 and the mutated proteins was compared and 
scored as follows: "++" indicates approximately the same 
amount of antibody binding, "+" indicates reduced bind-
ing to the mutated protein compared with PfCP-2.9, and 
"-" indicates no detectable antibody binding to the 
mutated protein.
ELISA was also performed to examine the difference in 
binding intensity between PfCP-2.9 and its mutated pro-
teins as described previously [9]. To avoid errors between 
the plates, PfCP-2.9 and its mutated proteins were coated 
in the same plate, while comparing with the same mAbs. 
MAb5.2 was adopted as an internal reference to assure 
that the proteins were equally coated, as the mapping of 
mAb5.2 had no overlapping epitope with the substitu-
tions that we synthesized on PfCP-2.9 [12]., The absor-
bance of PfCP-2.9 for each mAb was used to obtain the 
percentage of the reduction rate (Rr) for the mutated pro-
teins. The Rr value for the binding of a certain mAb was 
calculated as 100% - (A450 of a mutated protein/A450 of 
PfCP-2.9) ×100%. The recording method was similar to 
that in Western blot: "++" indicates about the same bind-
ing between PfCP-2.9 and mutated proteins with a Rr 
value within 25%; if the Rr value was between 25% and 
75%, a signal of "+" would be marked; finally, "-" was 
assigned when the Rr value was above 75%, indicating no 
detectable antibody binding of the mutated protein as 
compared with PfCP-2.9.
Results
Production and characterization of mAbs against PfCP-2.9
To identify epitopes of PfCP-2.9, a total of 12 mAbs rec-
ognizing the chimeric protein were prepared and charac-
terized. Determination of binding regions on PfCP-2.9 
for each mAb was investigated using recombinant 
PfAMA-1 protein (NIH) and PfMSP1-19 expressed from 
P. pastoris. The results showed that five mAbs (mAb2G, 
mAb7G, mAb10G, mAbG11.12 and mAbW9.10) recog-
nized the AMA-1 portion, and four (mAb13, mAb16, 
mAbW17 and mAbP5-W12) recognized PfMSP1-19 
epitopes, while the remaining three (mAb6G, mAb17, 
mAb18.20) failed to recognize either component of the 
chimeric protein in Western blot. PfCP-2.9 was further 
treated to determine whether its recognition by the mAbs 
was conformation-dependent. The results showed that Li et al. Malaria Journal 2010, 9:94
http://www.malariajournal.com/content/9/1/94
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Table 1: Primers for preparation of mutant genes by site-directed mutagenesis
Number Designation Directions Primer sequences (5' to 3')
01 M17
Forward CCATGTTCATTATTTAAAGATG
Reverse CCTTCATAATTTCATCTTTAAATAATGAAC
02 M18
Forward CATGTTCATTATATAGAGATG
Reverse CATCTCTATATAATGAACATG
03 M55
Forward CCGCTGATAATAAAGACTC
Reverse CCGGAGTCTTTATTATCAG
04 M56
Forward CCGCTGATGATAGAGACTC
Reverse CCGGAGTCTCTATCATCAG
05 M62
Forward CTTTAAAGTGTGCATGTGACCC
Reverse GGGTCACATGCACACTTTAAAG
06 M71
Forward GGTTTCACAAACTACATGTCG
Reverse CGACATGTAGTTTGTGAAACC
07 M81
Forward CTTTGTTTGTAAATGTATCGAAAGAAG
Reverse CTTCTTTCGATACATTTACAAACAAG
08 M82
Forward CGTTTCTTTGTTTGTAAATGTGTCCAAAGAAG
Reverse GCCCTTCTTTGGACACATTTACAAACAAAG
09 M84
Forward CGAAAGAAAGGCTGAAG
Reverse CTTCAGCCTTTCTTTCG
10 M159
Forward GCAATGTCCAGAAAATTCTG
Reverse CCAGAATTTTCTGGACATTG
11 M160
Forward GTCCACAAAGATCTGG
Reverse CCAGATCTTTGTGGAC
12 M165
Forward CCGGTTTCAAACATTTAG
Reverse CCGCTAAATGTTTGAAAC
13 M172
Forward GATGAAAGAGAATACTGTAAATG
Reverse CATTTACAGTATTCTCTTTCATC
14 M174
Forward CCGGAATGTAGATGTTTG
Reverse CCGCAAACATCTACATTCTTC
15 M176Li et al. Malaria Journal 2010, 9:94
http://www.malariajournal.com/content/9/1/94
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except for mAb2G, mAb16, mAb17 and mAb18.20, inter-
actions of the rest mAbs were reduction-sensitive. In 
addition, all the mAbs were detected for their ability to 
inhibit parasite growth in vitro by GIA and the results 
showed that six mAbs (mAb16, mAb17, mAbW17, 
mAb7G, mAb10G, and mAb13) had various levels of 
inhibitory activities from 9~32% The properties of the 
mAbs are summarized in Table 2.
Design and production of PfCP-2.9 mutants with single 
amino acid substitution
Seventeen mutants of the PfCP-2.9 with single amino 
acid substitution on either component of AMA-1 (III) or 
MSP1-19 were produced in Pichia pastoris. Figure 1A 
shows changes in location of the residues. Substitutions 
on the AMA-1 (III) component were selected as the 
highly conserved amino acids in different Plasmodium 
species [24] or amino acids within the epitope of mAb 
F8.12.10, which cross-reacts with several species of the 
Plasmodium [25]. These mutations were designed to dis-
cover possible functional epitopes on the AMA-1 (III) 
component. Some amino acid residues that participated 
in the formation of definitive blocking epitopes or those 
surface-exposed on the crystal structure of PfMSP1-19 
were also selected to investigate the corresponding 
epitopes on PfCP-2.9. A general description of the substi-
tutions is shown in Table 3.
To generate the PfCP-2.9 mutant genes, two overlapping 
fragments that carried the same point mutation were first 
produced by PCR amplification using the pfcp-2.9 gene 
as the template and then combined by the second round 
of PCR. The fragments and the final product of the 
mutant gene of m176 are representatively shown in Fig-
ure 1(B). Each PfCP-2.9 mutant was subsequently 
Forward GTAAATGTAGGTTGAATTACAAACAAGAAGG
Reverse CCTTCTTGTTTGTAATTCAACCTACATTTAC
16 M185
Forward GGTGATAGATGTGTTGAAAATCC
Reverse CCGCAACACATCTATCACC
17 M188
Forward GTGTTTTAAATCCACAACC
Reverse GGTTGTGGATTTAAAACAC
18 Universal
Forward CCCTCGAGAAAAGAGCTTTGTC
Reverse CCGGAATTCCTATTAATGATGATG
Table 1: Primers for preparation of mutant genes by site-directed mutagenesis (Continued)
Table 2: Properties of monoclonal antibodies against PfCP-2.9
Recognition
Designation PfCP-2.9 AMA-1 MSP-119 Reduction 
sensitivity
GIA (%)
mAb2G + + - - 0
mAb6G + - - + 0
mAb7G + + - + 12
mAb10G + + - + 10
mAbG11.12 + + - + 0
mAb13 + - + + 9
mAb16 + - + - 31
mAb17 + - - - 20
mAb18.20 + - - - 0
mAbW9.10 + + - + 0
mAbW17 + - + + 32
mAbP5-W12 + - + + 0Li et al. Malaria Journal 2010, 9:94
http://www.malariajournal.com/content/9/1/94
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sequenced before being transformed into P. pastoris for 
expression. The 17 PfCP-2.9 mutants were produced in 
Pichia system in a secreted form at various expression 
levels. The proteins were then purified by Ni-NTA affin-
ity chromotography. SDS-PAGE and Western blot analy-
ses of the PfCP-2.9 mutant proteins are shown in Figure 
1(D) and 1(E), respectively.
Effects of single amino acid substitution of PfCP-2.9 on 
mAb binding
The PfCP-2.9 and its mutants were assayed for mAb 
binding by both ELISA and Western blot. Epitope map-
ping of PfCP-2.9 with the mAbs is summarized in Table 4, 
and the main results of Western blot and ELISA are 
shown in Figure 2. Mutations in the AMA-1 (III) compo-
nent of PfCP-2.9 did not change the antibody binding sig-
nificantly, except that M62 (Phe491TAla) reduced the 
binding of mAb7G, mAbG11.12 and mAbW9.10; M82 
(Glu511TGln) reduced the binding of mAb7G and 
mAbW9.10, while M84 (Arg513TLys) only reduced the 
binding of mAb7G. Mutations in the MSP1-19 compo-
nent of PfCP-2.9 were relatively more informative. Simi-
larly, the binding of mAb6G and mAbP5-W12 was 
abolished by the replacement of either Gln14TGly (M159) 
or Glu43TLeu (M188) and reduced by the replacement of 
Lys40TIle (M185). However, they were different in the 
recognition of PfMSP1-19, i.e. both PfCP-2.9 and 
PfMSP1-19 were recognized by mAbP5-W12, while only 
the former was recognized by mAb6G. The substitution 
of Asn15TArg (M160) reduced the binding of most mAbs 
and abolished the binding of mAb6G and mAbP5-W12.
The bindings of the mAbs to PfCP-2.9 and its mutants in 
ELISA were largely in agreement with the results of the 
Western blot, with only one exception that the binding of 
mAb1E1 was abolished by M176 and reduced by M188 in 
ELISA; however, it was abolished by M176 or M188 and 
reduced by M159 in Western blot. Mutations that abol-
ished binding of the mAbs in immunoblot had an Rr 
value over 75%; those that reduced binding in the immu-
noblot had an Rr value between 25% and 75%, and those 
Table 3: General description of the substitutions made within PfCP-2.9
Location on 
PfCP-2.9
Positionb Amino acid
Designationa PfCP-2.9 Mutant Selection Reference
M17 AMA-1(III) 446 Tyr Phe c [24]
M18 AMA-1(III) 447 Lys Arg c [24]
M55 AMA-1(III) 484 Asp Asn c [24]
M56 AMA-1(III) 485 Lys Arg d [25]
M62 AMA-1(III) 491 Phe Ala d [25]
M71 AMA-1(III) 500 Ser Thr c [24]
M81 AMA-1(III) 510 Val Ile d [25]
M82 AMA-1(III) 511 Glu Gln c [24]
M84 AMA-1(III) 513 Arg Lys c [24]
M159 MSP1-19 14 Gln Gly e [19]
M160 MSP1-19 15 Asn Arg f [13]
M165 MSP1-19 20 Arg Glu e [19]
M172 MSP1-19 27 Glu Tyr f [13]
M174 MSP1-19 29 Lys Arg e [19]
M176 MSP1-19 31 Leu Arg f [13]
M185 MSP1-19 40 Lys Ile e [19]
M188 MSP1-19 43 Glu Leu f [13]
a. Mutated proteins are designated with the corresponding sequence number of the amino acid residues on PfCP-2.9
b. Positions for the substitutions numbered from the start of PfAMA-1 (3D7 line) or of PfMSP1-19 (Wellcome/K1 line).
c. Highly conserved amino acids across different Plasmodium species.
d. Epitopes recognized by mAbF8.12.19.
e. Surface-exposed amino acids on the PfMSP1-19 molecule.
f. Epitopes recognized by blocking mAbs.Li et al. Malaria Journal 2010, 9:94
http://www.malariajournal.com/content/9/1/94
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Figure 1 Production and identification of PfCP-2.9 mutants. (A) Schematic representation of site-directed mutagenesis of PfCP-2.9. The 17 mu-
tants were designated according to the positions of corresponding mutated amino acid resudues on PfCP-2.9. The N-terminal signal peptide (SP) and 
C terminal 6×His tag of each construct remained intact, and were involved in subsequent expression and purification, respectively. (B) Assembly of 
each mutant gene by overlap extension PCR method described in Method section. The 176 U was generated by PCR using the forward universal prim-
er and a reverse mutant primer, while the 176 D fragment generated using the reverse universal primer and a forward mutant primer. The two frag-
ments were combined to generate the entire mutant gene (176F) by PCR using the forward and reverse universal primers. (C) Purification of PfCP-2.9 
mutants by Ni-NTA chromotography. The supernatant of culture expressing M176 gene in P. pastoris was applied to Ni-NTA agarose columns. Pre- 
and post-column fraction as well as elution fractions with various concentration of imidazole was analyzed on a 12% SDS-PAGE gel, followed by Coo-
massie blue staining. (D) SDS-PAGE analysis of purificed PfCP-2.9 mutants. Each lane indicated each purified PfCP-2.9 mutant; (E) Western blot analysis 
of PfCP-2.9 mutants. Polyclonal rabbit antibodies to the PfCP-2.9 were used as the primary antibody for this detection.Li et al. Malaria Journal 2010, 9:94
http://www.malariajournal.com/content/9/1/94
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Figure 2 Western blot and ELISA analysis of interaction of mAbs with the PfCP-2.9 mutants. (A) Effects of PfCP-2.9 mutant containing a single 
amino acid substitution on the binding of the mAbs in Western blot. The mAbs indicated were used to investigate the binding differences between 
PfCP-2.9 and its mutant with a single amino acid substitution. Same amount of each purified protein was subjected to SDS-PAGE and Western blot. 
As indicated on the gel, reduced binding of the inhibitory mAb7G was observed in the mutants of M62 (Phe491 T Ala), M82 (Glu511 T Gln) and M84 
(Arg513 T Lys) compared to the binding of this mAb to the PfCP-2.9. Similarly, the binding of mAbW9.10 was reduced in M62 and M82, seperately. In 
addition, the binding of mAb1E1 was reduced in M159 (Gln14 T Gly) and M188 (Glu43 T Leu), and abolished in M185 (Lys40 T Ile). The bindings of two 
non-inhibitory antibodies, mAb6G and mAbP5-W12, were both reduced in M185 (Lys40 T Ile) and abolished in M159 and M188. (B), (C), (D), (E) and (F): 
Effects of PfCP-2.9 mutant on the binding of the mAbs in ELISA. Proteins coated were standardized by mAb5.2. The mAbs of 1E1, 7G, G11.12, W9.10 
and 6G were serially diluted by PBS-M, followed by a standard ELISA. Their binding differences between PfCP-2.9 and its mutated proteins are shown 
in (B) to (F). Data shown were repeatable in three separate experiments.L
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Table 4: Effects of single amino acid substitutions made within PfCP-2.9 on the binding of monoclonal antibodies
Antigens Amino acid Binding of monoclonal antibodies
PfCP-2.9 Mutant 7G 10G 13 16 17 W17 W9.10 G11.12 1E1 2G 6G 18.20 P5-W12 5.2
PfCP-2.9 ++ ++ ++ ++ ++ ++ ++ ++ ++ ++ ++ ++ ++ ++
M 1 7 T y r P h e + ++ ++ + + + + ++ + + + + + + ++ + + + + + + + + +
M 5 5 A s p A s n + ++ ++ + + + + ++ + + + + + + ++ + + + + + + + + +
M 5 6 L y s A r g + ++ ++ + + + + ++ + + + + + + ++ + + + + + + + + +
M62 Phe Ala + ++ ++ ++ ++ ++ ++ ++ ++ ++ ++ ++ ++
M 8 1 V a l I l e + ++ ++ + + + + ++ + + + + + + ++ + + + + + + + + +
M82 Glu Gln + ++ ++ ++ ++ ++ + ++ ++ ++ ++ ++ ++ ++
M84 Arg Lys + ++ ++ ++ ++ ++ ++ ++ ++ ++ ++ ++ ++ ++
M159 Gln Gly ++ ++ ++ ++ ++ ++ ++ ++ + ++ - ++ - ++
M160 Asn Arg + + +++ + + + ++ +- + - ++
M165 Arg Glu ++ ++ ++ ++ ++ ++ ++ ++ ++ ++ ++ ++ ++ ++
M172 Glu Tyr ++ ++ ++ ++ ++ ++ ++ ++ ++ ++ ++ ++ ++ ++
M174 Lys Arg ++ ++ ++ ++ ++ ++ ++ ++ ++ ++ ++ ++ ++ ++
M176 Leu Arg ++ ++ ++ ++ ++ ++ ++ ++ - ++ ++ ++ ++ ++
M185 Lys Ile ++ ++ ++ ++ ++ ++ ++ ++ ++ ++ + ++ + ++
M188 Glu Leu ++ ++ ++ ++ ++ ++ ++ ++ + ++ - ++ - ++
"++": strong binding; "+": reduced binding; "-": no bindingLi et al. Malaria Journal 2010, 9:94
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that had no effect on the binding in the immunoblot had 
an Rr value below 25%.
Discussion
PfCP-2.9 is a promising vaccine candidate among many 
worthy vaccines under development for prevention of 
malaria. It is made by fusing two blood-stage antigens 
(PfAMA-1 (III) and PfMSP1-19) through a hinge. 
Although animal experiments have demonstrated that 
this vaccine is much more immunogenic than either com-
ponent or the mixture of the two components, its func-
tional epitopes remain unclear.
To identify epitopes of PfCP-2.9, a panel of 12 mAbs were 
prepared in the present study, of which six showed vari-
ous levels of inhibitory activity as identified by GIA. The 
Western blot analysis showed that most of the inhibitory 
mAbs were sensitive to reduction, indicating that the dis-
ulfide-bond stabilized conformation is still critical for the 
chimeric protein, which is consistent with the previous 
work [9]. Interestingly, three of the mAbs only recognized 
PfCP-2.9, but not either component. Possibility of novel 
epitopes created by interaction of the two components 
was excluded through analysis of the nuclear magnetic 
resonance (NMR) solution structure of PfCP-2.9 [26]. 
The specificity of the mAbs needs to be further investi-
gated.
Epitope mapping was carried out by comparing mAb 
binding to PfCP-2.9 and its mutant proteins through 
Western blot and ELISA. Apparent binding changes are 
shown in Figure 2 and the epitopes associated with the 
changes were plotted onto the published three-dimen-
sional structure of PfAMA-1(III) [PDB: 1HN6] [20] and 
PfMSP1-19 [PDB: 1cej] [18] by the PyMOL software 
(DeLano Scientific, San Carlos, CA, USA) [27] as shown 
in Figure 3. The published structures of the individual 
components were used for the plotting analysis based on 
the fact that NMR solution structures of the individual 
components of PfCP-2.9 were not changed.
These findings may have the following implications:
(1) Of the six mAbs whose binding was reduced or abol-
ished by the mutations synthesized, only mAb7G exibited 
a mild inhibitory effect. This inhibitory epitope of 
mAb7G was found on the AMA-1 (III) component. The 
binding of mAb7G was reduced by any one of the three 
substitutions (M62: Phe491TAla, M82: Glu511TGln 
andM84: Arg513TLys). These three amino acids were all 
surface-exposed and clustered in the C-terminal unstruc-
tured region of AMA-1 (III), in close proximity to each 
other in conformation. The amino acid of Phe491 was 
involved in an epitope recognized by mAbF8.12.19, 
which was not inhibitory but involved in interspecies 
cross-reactivity [25]. Besides the direct steric blockage of 
AMA-1 function such as displayed by mAb4G2 [28], 
cross-linking and the consequent inhibition of AMA-1 
dispersion across the parasite surface have also been 
linked to invasion inhibition [28,29]. The mutation of 
M62 also disrupted the formation of a six-residue ring 
structure formed by Cys490-Cys507, Cys492-Cys509, Phe491 
and Arg508, which may be of functional importance on 
AMA-1 (III) [20]. These findings suggest that the amino 
acid of Phe491 is tightly associated with the formation of 
the inhibitory epitope of mAb7G. Glu511 and Arg513 are 
both highly conserved amino acids across different Plas-
modium species [24], and may also contribute to the for-
mation of the epitope. The binding of mAbG11.12 was 
reduced by M62 or M82, while the binding of mAbW9.10 
was only reduced by M62. Therefore, there is possibility 
that mAbG11.12 and mAbW9.10 could block the inhibi-
tory effect of mAb7G by competing at the position of 
both Phe491 and Glu511 and at the position of Phe491, 
respectively.
(2) Some information about blocking epitopes was 
obtained. It was found that four definitive amino acids 
(Asn15, Glu27, Leu31 and Glu43) were involved in the for-
mation of blocking epitopes on MSP1-19. It was reported 
[13] that mutation of these amino acids abolished the 
binding of blocking mAbs of mAb7.5, mAb2.2, mAb1E1 
and mAb111.4, respectively. ELISA was performed to 
detect mAb1E1 binding to PfCP-2.9 mutant, and the 
results showed that its binding was abolished by mutant 
M176 (Leu31TArg) and reduced by mutant M188 
(Glu43TLeu), which is consistent with the results from 
the mutants of PfMSP1-19 reported in other study [13]. 
There is a slight difference in the binding of mAb1E1 to 
the mutants by Western blot, which showed that the 
bindings to M176 and M188 were completely abolished. 
These results suggested that the residues of Leu31 and 
Glu43 were involved in the epitope of mAb1E1 on PfCP-
2.9. In addition, the bindings of both mAb6G and 
mAbP5-W12 were abolished by M159 (Gln14TGly) or 
M188 (Glu43TLeu), and reduced by M185 (Lys40TIle). 
However, these antibodies showed no biological activity 
in GIA.
(3) A vital amino acid of Asn15, found in the present 
study, may be of critical importance for the correct fold-
ing of PfCP-2.9, since the substitution of Asn15TArg on 
PfCP-2.9 reduced the binding of most mAbs and abol-
ished the binding of both mAb6G and mAbP5-W12.
Conclusions
This study focused on epitope mapping of PfCP-2.9 
through generation of a panel of mAbs against PfCP-2.9 
and a series of mutated proteins of PfCP-2.9 with single 
amino acid substitution. An inhibitory epitope on the 
AMA-1 (III) component, recognized by mAb7G, was 
associated with three amino acids, Phe491, Glu511 and 
Arg513. The amino acid residues of Gln14 and Glu43 were Li et al. Malaria Journal 2010, 9:94
http://www.malariajournal.com/content/9/1/94
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involved in the formation of a non-inhibitory epitope rec-
ognized by two mAbs, mAb6G and mAbP5-W12. The 
blocking epitope of PfCP-2.9 recognized by mAb1E1 was 
the same as that described previously on PfMSP1-19. 
These findings provide precise functional epitopes on 
PfCP-2.9 and may prove useful in directing the design of 
more effective malaria vaccines.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
CL participated in the study design, experiments and data analysis, and wrote 
the manuscript; RW established the hybridoma cell lines and participated in 
the production and identification of mAbs; YW participated in the production 
and characterization of the mAbs; DZ participated in the study design and data 
analysis, ZH participated in the construction and expression of the mutated 
proteins; WP conceived of the study, participated in its design and data analy-
sis, and contributed to manuscript writing and editing. All authors read and 
approved the final manuscript.
Acknowledgements
This work was supported by grants from the National Basic Research Program 
(973 Program) in China (2007CB513100), the National Natural Science Founda-
tion of China (No.30430610), the National 863 Program in China 
(2006AA02A222), National S & T Major Project (2008ZX10004-011) and Shang-
hai Leading Academic Discipline Project (No. B901). We thank Dr Feng Qian for 
invaluable advice and Aiguo Zhou for technical assistance.
Author Details
Department of Pathogenic Biology, Second Military Medical University, 800 
Xiang Yin Road, Shanghai 200433, China
References
1. World Health Organization: World Malaria Report 2008.   Geneva 2008.
2. O'Donnell RA, Saul A, Cowman AF, Crabb BS: Functional conservation of 
the malaria vaccine antigen MSP-119across distantly related 
Plasmodium species.  Nature medicine 2000, 6:91-95.
3. Triglia T, Healer J, Caruana SR, Hodder AN, Anders RF, Crabb BS, Cowman 
AF: Apical membrane antigen 1 plays a central role in erythrocyte 
invasion by Plasmodium species.  Mol Microbiol 2000, 38:706-718.
4. Harris PK, Yeoh S, Dluzewski AR, O'Donnell RA, Withers-Martinez C, 
Hackett F, Bannister LH, Mitchell GH, Blackman MJ: Molecular 
identification of a malaria merozoite surface sheddase.  PLoS Pathogens 
2005, 1:241-251.
5. Howell SA, Well I, Fleck SL, Kettleborough C, Collins CR, Blackman MJ: A 
single malaria merozoite serine protease mediates shedding of 
multiple surface proteins by juxtamembrane cleavage.  J Biol Chem 
2003, 278:23890-23898.
6. Howell SA, Withers-Martinez C, Kocken CH, Thomas AW, Blackman MJ: 
Proteolytic processing and primary structure of Plasmodium falciparum 
apical membrane antigen-1.  J Biol Chem 2001, 276:31311-31320.
7. O'Donnell RA, Blackman MJ: The role of malaria merozoite proteases in 
red blood cell invasion.  Curr Opin Microbiol 2005, 8:422-427.
8. Zhang Q, Xue X, Qu L, Pan W: Construction and evaluation of a 
multistage combination vaccine against malaria.  Vaccine 2007, 
25:2112-2119.
9. Pan W, Huang D, Zhang Q, Qu L, Zhang D, Zhang X, Xue X, Qian F: Fusion 
of two malaria vaccine candidate antigens enhances product yield, 
immunogenicity, and antibody-mediated inhibition of parasite growth 
in vitro.  J Immunol 2004, 172:6167-6174.
10. Hu J, Chen Z, Gu J, Wan M, Shen Q, Kieny MP, He J, Li Z, Zhang Q, Reed ZH, 
et al.: Safety and immunogenicity of a malaria vaccine, Plasmodium 
falciparum AMA-1/MSP-1 chimeric protein formulated in montanide 
ISA 720 in healthy adults.  PloS One 2008, 3:e1952.
11. Malkin E, Hu J, Li Z, Chen Z, Bi X, Reed Z, Dubovsky F, Liu J, Wang Q, Pan X, 
et al.: A phase 1 trial of PfCP2.9: an AMA1/MSP1 chimeric recombinant 
protein vaccine for Plasmodium falciparum malaria.  Vaccine 2008, 
26:6864-6873.
12. Dekker C, Uthaipibull C, Calder LJ, Lock M, Grainger M, Morgan WD, 
Dodson GG, Holder AA: Inhibitory and neutral antibodies to 
Plasmodium falciparum MSP119 form ring structures with their 
antigen.  Mol Biochem Parasitol 2004, 137:143-149.
13. Uthaipibull C, Aufiero B, Syed SE, Hansen B, Guevara Patino JA, Angov E, 
Ling IT, Fegeding K, Morgan WD, Ockenhouse C, Birdsall B, Feeney J, Lyon 
JA, Holder AA: Inhibitory and blocking monoclonal antibody epitopes 
on merozoite surface protein 1 of the malaria parasite Plasmodium 
falciparum.  J Mol Biol 2001, 307:1381-1394.
14. Nwuba RI, Sodeinde O, Anumudu CI, Omosun YO, Odaibo AB, Holder AA, 
Nwagwu M: The human immune response to Plasmodium falciparum 
includes both antibodies that inhibit merozoite surface protein 1 
secondary processing and blocking antibodies.  Infect Immun 2002, 
70:5328-5331.
15. Miura K, Zhou H, Moretz SE, Diouf A, Thera MA, Dolo A, Doumbo O, Malkin 
E, Diemert D, Miller LH, Mullen GE, Long CA: Comparison of biological 
activity of human anti-apical membrane antigen-1 antibodies induced 
by natural infection and vaccination.  J Immunol 2008, 181:8776-8783.
16. Morgan WD, Lock MJ, Frenkiel TA, Grainger M, Holder AA: Malaria 
parasite-inhibitory antibody epitopes on Plasmodium falciparum 
merozoite surface protein-1(19) mapped by TROSY NMR.  Mol Biochem 
Parasitol 2004, 138:29-36.
17. Morgan WD, Frenkiel TA, Lock MJ, Grainger M, Holder AA: Precise epitope 
mapping of malaria parasite inhibitory antibodies by TROSY NMR 
cross-saturation.  Biochemistry 2005, 44:518-523.
18. Morgan WD, Birdsall B, Frenkiel TA, Gradwell MG, Burghaus PA, Syed SE, 
Uthaipibull C, Holder AA, Feeney J: Solution structure of an EGF module 
pair from the Plasmodium falciparum merozoite surface protein 1.  J 
Mol Biol 1999, 289:113-122.
19. Pizarro JC, Chitarra V, Verger D, Holm I, Petres S, Dartevelle S, Nato F, 
Longacre S, Bentley GA: Crystal structure of a Fab complex formed with 
PfMSP1-19, the C-terminal fragment of merozoite surface protein 1 
from Plasmodium falciparum : a malaria vaccine candidate.  J Mol Biol 
2003, 328:1091-1103.
20. Nair M, Hinds MG, Coley AM, Hodder AN, Foley M, Anders RF, Norton RS: 
Structure of domain III of the blood-stage malaria vaccine candidate, 
Plasmodium falciparum apical membrane antigen 1 (AMA1).  J Mol Biol 
2002, 322:741-753.
21. Kohler G, Milstein C: Continuous cultures of fused cells secreting 
antibody of predefined specificity.  Nature 1975, 256:495-497.
22. Ho SN, Hunt HD, Horton RM, Pullen JK, Pease LR: Site-directed 
mutagenesis by overlap extension using the polymerase chain 
reaction.  Gene 1989, 77:51-59.
23. Bordo D, Argos P: Suggestions for "safe" residue substitutions in site-
directed mutagenesis.  J Mol Biol 1991, 217:721-729.
24. Chesne-Seck ML, Pizarro JC, Vulliez-Le Normand B, Collins CR, Blackman 
MJ, Faber BW, Remarque EJ, Kocken CH, Thomas AW, Bentley GA: 
Structural comparison of apical membrane antigen 1 orthologues and 
paralogues in apicomplexan parasites.  Mol Biochem Parasitol 2005, 
144:55-67.
25. Igonet S, Vulliez-Le Normand B, Faure G, Riottot MM, Kocken CH, Thomas 
AW, Bentley GA: Cross-reactivity studies of an anti-Plasmodium vivax 
apical membrane antigen 1 monoclonal antibody: binding and 
structural characterisation.  J Mol Biol 2007, 366:1523-1537.
26. Peng H, Hu Y, Zhou A, Jin C, Pan W: Solution structure of a Plasmodium 
falciparum AMA-1/MSP 1 chimeric protein vaccine candidate (PfCP-2.9) 
for malaria.  Malar J 2010, 9:76.
27. DeLano W: The PyMOL User's Manual.  San Carlos, California: DeLano 
Scientific; 2002. 
28. Dutta S, Haynes JD, Barbosa A, Ware LA, Snavely JD, Moch JK, Thomas AW, 
Lanar DE: Mode of action of invasion-inhibitory antibodies directed 
against apical membrane antigen 1 of Plasmodium falciparum.  Infect 
Immun 2005, 73:2116-2122.
29. Dutta S, Haynes JD, Moch JK, Barbosa A, Lanar DE: Invasion-inhibitory 
antibodies inhibit proteolytic processing of apical membrane antigen 
1 of Plasmodium falciparum merozoites.  Proc Natl Acad Sci USA 2003, 
100:12295-12300.
Received: 14 September 2009 Accepted: 12 April 2010 
Published: 12 April 2010
This article is available from: http://www.malariajournal.com/content/9/1/94 © 2010 Li et al; licensee BioMed Central Ltd.  This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Malaria Journal 2010, 9:94Li et al. Malaria Journal 2010, 9:94
http://www.malariajournal.com/content/9/1/94
Page 12 of 12
doi: 10.1186/1475-2875-9-94
Cite this article as: Li et al., Epitope mapping of PfCP-2.9, an asexual blood-
stage vaccine candidate of Plasmodium falciparum Malaria Journal 2010, 
9:94